ENDO: Novel Male Contraceptive Gel May Achieve Faster Sperm Suppression
12 Jun 2024
Clinical ResultPhase 2
WEDNESDAY, June 12, 2024 -- A novel male contraceptive gel suppresses sperm production faster than other hormone-based methods for male birth control, according to a phase 2 study presented at the annual meeting of the Endocrine Society, held from June 1 to 4 in Boston.
Danielle Gross, from the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health in Bethesda, Maryland, and colleagues assessed the time to sperm suppression (concentration ≤1 million/mL) with daily self-administration of segesterone acetate (8 mg)/testosterone (74 mg) combination gel in 222 healthy men.
The researchers found that 86 percent of participants achieved suppression to ≤1 million/mL during treatment. One in five participants (21 percent) were suppressed to ≤1 million/mL at five weeks, which increased to 52 percent by eight weeks and 64 percent by nine weeks. The median time for those achieving suppression was eight weeks, with 82 percent suppressed within 12 weeks and 86 percent at 15 weeks of initiating treatment.
"The development of a safe, highly effective and reliably reversible contraceptive method for men is an unmet need," senior author Diana Blithe, Ph.D., also of the National Institutes of Health, said in a statement. "While studies have shown that some hormonal agents may be effective for male contraception, the slow onset of spermatogenic suppression is a limitation."
Press Release
More Information
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.